PLX Stock Summary and Trading Ideas (Protalix Biotherapeutics (De) | AMEX:PLX)

Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.

Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.

As of June 9, 2026, PLX stock price climbed to $1.98 with 452,139 million shares trading.

PLX has a beta of 1.85, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.10 to the broad based SPY ETF.

PLX has a market cap of $159.53 million. This is considered a Micro Cap stock.

Last quarter Protalix Biotherapeutics (De) reported $34 million in Revenue and $.22 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $.23.

In the last 3 years, PLX traded as high as $3.19 and as low as $.82.

The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, DFAS, IWC.

PLX has outperformed the market in the last year with a return of +25.3%, while the SPY ETF gained +24.3%. However, in the most recent history, PLX shares have underperformed the stock market with its stock returning -24.4% in the last 3 month period and -5.7% for the last 2 week period, while SPY has returned +9.9% and -1.2%, respectively.

PLX support price is $1.90 and resistance is $2.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.